Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements8/28 19:00TDnetPDF(140KB)
Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)8/12 8:30TDnetPDF(120KB)
当社に関するレポートについて「Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns」に対する当社の見解8/12 8:30TDnetPDF(87KB)
Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”8/7 12:57TDnetPDF(224KB)
当社に関するレポートについて(「Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 Billion yen Swiss Shuffle」に関する追加説明)8/7 12:56TDnetPDF(283KB)
Supplementary Financial Data (IFRS) for the Three Months Ended June 30, 20267/31 15:30TDnetPDF(279KB)
Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 [IFRS]7/31 15:30TDnetPDF(485KB)
Other Matters Subject to Measures for Electronic Provision for the 206th Annual Shareholders’ Meeting5/29 8:00TDnetPDF(548KB)
Notice Regarding Results of Capital Increase by way of Third-Party Allotment (Not Implemented)5/22 16:40TDnetPDF(219KB)